BioSpace - Financial Content

SUPERGEN Add to My Watchlist

(NSDQ: SUPG)

Detailed Quote

Last Price	2.72 (11.20.09 5:20 PM EST)
Change (%)	+0.02 (+0.74%)
Volume	141,300
Open	2.69
Previous Close	2.70
Day High	2.75
Day Low	2.69
Bid	2.72 x 14500
Ask	2.74 x 5800

Average Volume	242,492
Shares Outstanding	60.14M
Market Cap	163.6M
Year High	3.30
Year Low	1.54
Earnings Per Share	-0.01
P/E Ratio	-
Dividend	N/A
Yield	N/A

Intraday

3 Month

6 Month

1 Year

Symbol	Last	Change (%)
CRY	6.11	+0.00 (+0.00)
SMTS	14.38	+0.21 (+1.48%)
WUYIF	0.10	+0.00 (+0.00)
DEPO	3.30	+0.03 (+0.92%)
STXS	3.83	-0.09 (-2.30%)
TRCR	18.48	-0.68 (-3.55%)
TOMO	3.17	-0.04 (-1.25%)

Wed, Nov 11, 2009
	SuperGen to Present at Lazard Healthcare Conference on November 18, 2009 - Business Wire
Mon, Nov 09, 2009
	SuperGen Presentations at AACR-NCI-EORTC - Business Wire
Wed, Nov 04, 2009
	Southwest IDEAS Conference Announces Presenting Company Lineup, Lunch Programs - GlobeNewswire
	SuperGen to Present at Merriman Curhan Ford Investor Summit on November 10, 2009 - Business Wire
Wed, Oct 28, 2009
	StockSource.us Reports on Break Out Stock - MNDP - EmailWire.Com Press ...
More Press Releases

Wed, Nov 11, 2009
	Today's 5-Star Movers Maybe what glitters really is gold. - Fool.com Headlines
Mon, Nov 09, 2009
	SuperGen (SUPG) Presentations at AACR-NCI-EORTC SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced the acceptance of seven abstracts for poster presentations on November 16, 17 and 18, 2009 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston, MA. SuperGen’s presentations will review clinical and non-clinical advances in the following compounds: MP-470, SGI-1776, SGI-110, SGI-1252, as well as two presentations on the Etk program. SuperGen (SUPG)is a pharmaceutical company dedicated to the discovery and development of novel cancer therapeutics in epigenetic and cell signaling modulation. The Company develops products through biochemical and clinical proof of concept to partner for further development and commercialization - Benzinga
Wed, Nov 04, 2009
	SuperGen (SUPG) Announces Investor Summit on November 10, 2009 SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that Mohammad Azab, M.D., Chief Medical Officer, will present at the Merriman Curhan Ford 6th Annual Investor Summit on Tuesday November 10, 2009 in New York. SuperGen is a pharmaceutical company dedicated to the discovery and development of novel cancer therapeutics in epigenetic and cell signaling modulation. The Company develops products through biochemical and clinical proof of concept to partner for further development and commercialization. - Benzinga
Mon, Nov 02, 2009
	5-Star Stocks on the Upswing Check out these newly minted five-star stocks. - Fool.com Headlines
Mon, Oct 26, 2009
	SuperGen, Inc. Q3 2009 Earnings Call Transcript SuperGen, Inc. (SUPG) Q3 2009 Earnings Call October 26, 2009 4:30 pm ET Complete Story » - Transcripts from See...
More News

Wed, Nov 18, 2009

Zacks #1 Rank Additions for Wednesday – Zacks Tale of the Tape - Stock Market News & ...

Wed, Nov 11, 2009

(ASH) Investing in the Biotech Sector: Here’s An Easy Way to Profit from Biotech Stocks - Stock Blog Hub

(SNTS) Top Performer for Wed: Santarus- Zacks #1 Rank Top Performers - Stock Blog Hub

Investing In The Biotech Sector: Here’s An Easy Way To Profit From Biotech Stocks - home: iStockAnalyst....

Top Performer for Wed: Santarus (SNTS) – Zacks #1 Rank Top Performers

Shares of Santarus, Inc. (SNTS) have moved north of 7.5% this morning, which has made this specialty biopharmaceutical company a top-performing Zacks #1 Rank stock.

Last week, the company announced third-quarter results that included another positive earnings per share surprise, as well as a raised 2009 guidance.

Earnings estimates have responded in kind by gaining in the past 7 trading days. Volume on Wednesday is approximately 317,000 shares, which is above the daily average of nearly 250,000.

Santarus focuses on acquiring, developing and commercializing proprietary products for the prevention and treatment of gastrointestinal diseases and disorders. Its efforts are focused on ZEGERID® for the treatment of certain upper GI diseases and disorders, and GLUMETZA® to improve glycemic control in adults with type 2 diabetes.

SNTS is 1 of 4 companies from the Medical-Drugs industry on the Zacks #1 Rank List, which today includes 225 stocks in total. The other 3 names are AstraZeneca plc (AZN), SuperGen, Inc. (SUPG) and Valeant Pharmaceuticals International (VRX).

Earnings Estimates

Since its third-quarter report on Nov 4, Santarus has enjoyed sharp gains in analysts' earnings estimates. The Zacks Consensus Estimate for this year is at 30 cents per share, marking a rise of more than 66% from 18 cents in just the past 7 trading days. The 4 covering analysts have unanimously contributed to this upward revision.

At the moment, the Zacks Consensus Estimate for next year is at 22 cents, marking a gain of 10% in the past week from 20 cents.

Raised 2009 Guidance

In its third-quarter report, Santarus boosted its guidance for 2009 based on a solid performance for that period, revenue growth for ZEGERID and GLUMETZA, its growth expectation for lower overall expenses, and the signing of its licensing agreement for Europe.

SNTS now expects product-related revenue of at least $141 million, instead of its previous outlook of $138 million, and also raised its total revenues expectation to at least $150 million, instead of $145 million. The company now expects net income of at least $10 million, versus breakeven to $1 million earlier, and reduced its estimate for 2009 R&D expenses.

For the quarter itself, Santarus earned 9 cents per share, which was sharply higher than the Zacks Consensus Estimate for a loss of a penny per share. It was also significantly better than the year-ago loss of 8 cents.

The medical/biotech industries can be very volatile, but SNTS has been able to consistently beat the quarterly Zacks Consensus Estimate. In the past 4 quarters, it has amassed an average surprise of more than 500%. (In each of those quarters, the company reported a profit while the Zacks Consensus Estimate was pegging a loss.)

Total revenues for Santarus advanced to $39.5 million in the quarter from $32.2 million, while product-related revenue advanced about 30% to $38.3 million from $29.5 million. Total prescriptions for ZEGERID and GLUMETZA rose, respectively, by 6.3% year over year and 9.2% sequentially.

Zacks Investment Research

- Stock Market News & ...

More Blogs

Thu, Sep 21, 2006
	SuperGen, Inc. Small Cap Investment Conference - VCall Podcasts
Fri, Jun 23, 2006
	Wall Street to Main Street: News, Views and Commentary: June 23, 2006 Merck, Medifast, Neurocrine Biosciences, Concord Career Colleges, Aspreva Pharmaceuticals, Novell Inc - NAMC Radio
More Podcasts

10/26/09		Q3 2009 Earnings Archive for SUPG
09/23/09		Special Conference 2009 Global Life Sciences Conference Archive for SUPG
09/10/09		Special Conference SuperGen, Inc. to Present At Annual Rodman and Renshaw Healthcare Conference Archive for SUPG
07/27/09		Q2 2009 Earnings Archive for SUPG
04/27/09		Q1 2009 Earnings Archive for SUPG

Powered By: FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes.
All other data is delayed at least 20 minutes.
By accessing this page, you agree to the following terms and conditions.
Investing News provided by MarketMinute.com
Stock Analysis provided by SocialPicks Conference calls info supplied by OpenCompany
Fundamental data supplied by Mergent, Inc.
Stock quote data supplied by Telekurs